

**Freedom of Information Act Disclosure log
- Reply Extract**

File reference	W21FOI127
Key words	Trends in Cancer Treatment
Date of release	13/08/2021
Attachments	No

You asked

1. In the past 3 months, how many Urothelial cancer patients were treated with the following:

- **Atezolizumab = 0**
- **Carboplatin with Gemcitabine = Five or fewer**
- **Carboplatin single or in any other combination: Carboplatin & etoposide = Five or fewer**
- **Cisplatin with Gemcitabine = Five or fewer**
- **Cisplatin single or in any other combination: Cisplatin & etoposide = Five or fewer**
- **Nivolumab = 0**
- **Pembrolizumab = Five or fewer**
- **Any other regimen including Paclitaxel = 0**
- **Any other chemotherapy regimen:**
Denosumab = Five or fewer
Gemcitabine & RT = Five or fewer
- **Other active systemic anti-cancer therapy [please state]**
- **Palliative care only = 0**

Used systemic anti-cancer therapy (SACT) data 1/3/21 – 31/5/21 and ICD codes C67 – C67.9 (bladder) to identify those patients that have had a cycle prescribed during this time

2. Does your Trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

The Trust completes a non-disclosure agreement when it participates in clinical trials because the information is commercially sensitive. The Trust would breach the conditions of any agreement and reveal commercially sensitive information if it were to provide an answer to this question. This would constitute a breach of confidence that would be actionable in court by that or any other person. The Trust is refusing to supply the information in compliance with section 41.-(2).

3. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- **Afatinib** = 6
- **Alectinib** = 7
- **Atezolizumab monotherapy** = Five or fewer
- **Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel** = Five or fewer
- **Bevacizumab** = 0
- **Brigatinib** = 0
- **Ceritinib** = Five or fewer
- **Crizotinib** = Five or fewer
- **Dacomitinib** = 0
- **Dabrafenib with Trametinib** = 0
- **Docetaxel** = Five or fewer
- **Durvalumab** = Five or fewer
- **Erlotinib** = 0
- **Gefitinib** = 0
- **Gemcitabine** = 0
- **Nintedanib with Docetaxel** = Five or fewer
- **Nivolumab** = 0
- **Osimertinib** = Five or fewer
- **Paclitaxel** = 0
- **Pembrolizumab monotherapy** = 28
- **Pembrolizumab chemo in combination:**
Pembrolizumab, carboplatin & pemetrexed = 7
Pembrolizumab, carboplatin & paclitaxel = Five or fewer
- **Pemetrexed with Carboplatin** = Five or fewer
- **Pemetrexed with Cisplatin** = 0
- **Vinorelbine and cisplatin/carboplatin:**
Carboplatin & vinorelbine = 6
Cisplatin & vinorelbine = Five or fewer
- **Any other active systemic anti-cancer therapy**
Atezolizumab, carboplatin & etoposide = Five or fewer
Carboplatin & etoposide – 14
Carboplatin & paclitaxel = Five or fewer
Denosumab – 6
Entrectinib = Five or fewer
Everolimus = Five or fewer
Lorlatinib = Five or fewer
Pemetrexed (single agent) = Five or fewer
Topotecan = Five or fewer
- **Palliative care only** = 20

Used SACT data 1/3/21 – 31/5/21 and ICD codes C34 – C34.9 (lung – unable to differentiate just NSCLC patients) to identify those patients that have had a cycle prescribed during this time

4. **Does your trust participate in any ongoing clinical trials for the treatment of non-small cell lung cancer (NSCLC)? If so, can you please provide the name of each trial along with the number of patients taking part?**

The Trust completes a non-disclosure agreement when it participates in clinical trials because the information is commercially sensitive. The Trust would breach the conditions of any agreement and reveal commercially sensitive information if it were to provide an answer to this question. This would constitute a breach of confidence that would be actionable in court by that or any other person. The Trust is declining to supply the information in compliance with section 41.(2).

Legal notes:

University Hospitals Plymouth NHS Trust is confirming in accordance with section 1 (a) of the Act that it holds the information requested and is supplying it in accordance with section 1(b), unless otherwise specified below and for that reason

It constitutes personal information.

Please find the answers to your questions noting that we have redacted the data set where numbers are five or fewer. Figures of five or fewer are considered personally identifiable information. Our approach avoids a breach of the first two Data Protection Act principles and the general right to object to processing, whilst providing you with as much detail as possible. This is in accordance with section 40.(2)(a) and (b) by virtue of the first and second condition.

The information is or would be provided in confidence as part of a non-disclosure agreement because it or would be commercially sensitive.

Section 41 can apply if

- it was obtained by the authority from any other person,
- its disclosure would constitute a breach of confidence.
- a legal person could bring a court action for that breach of confidence, and
- that court action would be likely to succeed

Section 41(2) provides an exclusion from the duty to confirm or deny whether information is held. This exclusion applies if confirming or denying that information is held would in itself give rise to a breach of confidence, actionable by any person, that would be likely to succeed.

Section 43 the commercial Interest exemption has not been applied because we are relying on section 41 however at review any review should consider the use of section 43(2 and 3)

Attachments included: No



**University Hospitals
Plymouth**
NHS Trust